statements

SMC Announces Marketing Agreement with Plato Technologies. Inc.

Source Node:
Time Stamp: April 19, 2024 5:45 AM - Modified On: April 19, 2024 - Published By:
Source Cluster:
Republished By Plato

  BOCA RATON, FL / Plato / Amplifi / April 18,2024 / SMC Entertainment, Inc. ("SMC" or the "Company") (OTC PINK: SMCE) SMC / (PINK:SMCE) is pleased to announce a marketing agreement and collaboration with Plato Technologies Inc. Plato Technologies specializes in AI content disruption and AI management systems. The collaboration will enable the Company to market Plato's platform directly to web and content development teams. The companies have agreed on a revenue sharing agreement after deducting individual client acquisition costs. "This is just the beginning." stated Erik Blum CEO

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Source Node:
Time Stamp: April 15, 2024 1:26 PM - Modified On: April 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology New York, March 12, 2024 - (Plato Data) - Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology. The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related

[Mirror] Quadratic Arithmetic Programs: from Zero to Hero

Source Node:
Time Stamp: February 2, 2024 10:43 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/quadratic-arithmetic-programs-from-zero-to-hero-f6d558cea649 There has been a lot of interest lately in the technology behind zk-SNARKs, and people are increasingly trying to demystify something that many have come to call "moon math" due to its perceived sheer indecipherable complexity. zk-SNARKs are indeed quite challenging to grasp, especially due to the sheer number of moving parts that need to come together for the whole thing to work, but if we break the technology down piece by piece then

Curio and Deep Isolation Sign MOU to Advance Nuclear Waste Disposal Technologies.

Source Node:
Time Stamp: December 7, 2023 3:23 PM - Modified On: December 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington, D.C, December 7, 2023 — Curio, a trailblazer in nuclear technology solutions, and Deep Isolation, an innovator in nuclear waste disposal, have entered into a Memorandum of Understanding (MOU) to collectively drive forward the development of advanced technologies for efficient and secure disposal of high-level nuclear waste (HLW). Under this MOU, both Curio and Deep Isolation will mutually collaborate and exchange critical information for the use of Deep Isolation’s Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for the isolation and management of HLW

GMEX ZERO13 wins COP28 TechSprint and continues network expansion

Source Node:
Time Stamp: December 6, 2023 5:56 AM - Modified On: December 6, 2023 - Published By:
Source Cluster:
Republished By Plato

Technology solution selected as winner for blockchain technology British innovation in digital sustainable finance showcased and recognised at COP28 Universal Carbon Registry, Decarb.earth, Koat Intelligence Solutions and Plato Data Intelligence added LONDON, UAE, 6 December 2023 – ZERO13, the GMEX Group initiative providing a digital climate fintech platform-as-a-service, is delighted to announce the addition of four new participants to its Asset Settlement Network and its selection as the winner of the prestigious COP28 TechSprint for blockchain technology. The COP28 TechSprint, launched by the Central Bank of the United Arab Emirates

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers

American Picture House Corporate Update

Source Node:
Time Stamp: September 6, 2023 4:28 PM - Modified On: September 6, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, NY, Raleigh, NC, and Los Angeles, CA.  September 6, 2023 – American Picture House Corporation (OTC: APHP), an entertainment company with a focus on producing feature films, limited series, and entertainment enhancing technologies, today provided a corporate update for shareholders. Industry Strikes American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution. Update on Feature Films -

Starbox Group’s StarboxAI – ViPro Module: Transforming Content Creation

Source Node:
Time Stamp: September 5, 2023 12:41 PM - Modified On: September 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Kuala Lumpur, Malaysia, Sept 5th, 2023 – Starbox Group Holdings Ltd. (Nasdaq: STBX), a dynamic player in cash rebates, digital advertising, and payment solutions, with a vision of leading in artificial intelligence (“AI”) solutions throughout Southeast Asia, is making waves with the launch of its groundbreaking StarboxAI - ViPro module. This innovative module introduces a text-to-video feature set to redefine content creation. The Text-to-Video feature within the StarboxAI - ViPro module is not just an addition; it's a revelation. It empowers content creators to seamlessly transmute textual instructions or scripts

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement